Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding
diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and
immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α
monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior
corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is
multicenter randomized, parallel-treatment, comparative effectiveness trial comparing
adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in
the treatment of non-infectious, intermediate, posterior, and panuveitides.